BIT
BIOTRON LIMITED
$0.0020
0.00%
Market cap
$6M
Turnover
$4,112
Last price
$0.0020
Day change
0.00%
Announcements
10
Range, past year
Open 0.004 · Low 0.001 · Now 0.002 · High 0.005
Open BIT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
BIT momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
9/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
+0.0%
1 Year
-50.0%
RSI
50
Avg daily range
19.5%
BIOTRON LIMITED scores 9 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -66.7%
- High volatility (ATR 19.5%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
BIT announcements
Recent price-sensitive releases.
- 2026-11-09 Executive Director CEO Commences - Appendix 3X CEO/Managing Director - Appointment Resignation | Initial Director's Interest Notice
- 2026-10-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-14 Appointment of CEO and Executive Director CEO/Managing Director - Appointment Resignation | Director Appointment/Resignation
- 2026-09-14 Resignation of Managing Director and Appendix 3Z CEO/Managing Director - Appointment Resignation | Final Director's Interest Notice
- 2026-08-27 Full Year Statutory Accounts and Appendix 4E Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-21 Quarterly Activities/Appendix 4C Cash Flow Report
- 2026-07-13 Sedarex First Milestone Met
More Health Care stocks
Most traded in the same sector.